Erasca Reports 44% Pancreatic Tumor Response
Erasca reported encouraging early Phase 1 results for its experimental pan-RAS drug ERAS-0015, including a 44% confirmed response rate among 25 previously treated pancreatic cancer patients and a 69% rate among 13 patients with KRAS G12D or G12V tumors. Responses were also reported in small groups with lung and biliary tract cancers, while early combination studies showed antitumor activity and no dose-limiting toxicities in the reported cohorts. Side effects were mostly low grade, but severe treatment-related events occurred and a previously reported case of pneumonitis at a lower dose was fatal; follow-up remains too short to determine how durable responses are. Erasca also shared preliminary Phase 1 data for its separate pan-KRAS drug ERAS-4001 and plans to advance ERAS-0015 studies, including accelerating a first-line pancreatic cancer Phase 3 trial to the first half of 2027. Both drugs remain investigational, and larger trials are needed to establish their safety and effectiveness.



